General Information of Drug (ID: DM8DYJQ)

Drug Name
SHP656 Drug Info
Indication
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Preclinical [1]
Cross-matching ID
TTD Drug ID
DM8DYJQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-Ethoxypropanoic acid DMAM4FE Breast cancer 2C60-2C65 Preclinical [2]
KL001 DMHX1LA Glioblastoma of brain 2A00.00 Preclinical [3]
TH301 DM4BDGW Glioblastoma of brain 2A00.00 Preclinical [1]
KL044 DMG3FDE Discovery agent N.A. Investigative [4]
Drug(s) Targeting Cryptochrome-2 (CRY2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-Ethoxypropanoic acid DMAM4FE Breast cancer 2C60-2C65 Preclinical [2]
KL001 DMHX1LA Glioblastoma of brain 2A00.00 Preclinical [3]
TH301 DM4BDGW Glioblastoma of brain 2A00.00 Preclinical [1]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cryptochrome circadian clock 1 (CRY1) TT5MLZR CRY1_HUMAN Modulator [1]
Cryptochrome-2 (CRY2) TTAO58M CRY2_HUMAN Modulator [1]

References

1 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
2 The cryptochrome inhibitor KS15 enhances E-box-mediated transcription by disrupting the feedback action of a circadian transcription-repressor complex. Life Sci. 2018 May 1;200:49-55.
3 Identification of small molecule activators of cryptochrome. Science. 2012 Aug 31;337(6098):1094-7.
4 Development of Small-Molecule Cryptochrome Stabilizer Derivatives as Modulators of the Circadian Clock. ChemMedChem. 2015 Sep;10(9):1489-97.